文献速递炎症性肠病

炎症性肠病患者从静脉英夫利西单抗转换为皮下制剂的疗效:REMSWITCH研究

Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-08-17

多中心观察性研究纳入184例临床缓解的炎症性肠病患者,其中72.3%同意转换为皮下英夫利西单抗120 mg每2周一次。第3次访视时,不同静脉维持方案患者的复发率从7.3%至66.7%不等(P<.001),10 mg/kg每4周方案及基线粪钙卫蛋白>250 μg/g与复发风险升高相关;剂量增至240 mg每2周一次可使93.3%复发患者重新获得临床缓解。

要点

  • 临床缓解的炎症性肠病患者转换为皮下英夫利西单抗120 mg每2周一次总体安全且接受度高。
  • 10 mg/kg每4周静脉方案患者转换后复发风险最高(66.7%),需240 mg每2周一次剂量递增。
  • 基线粪钙卫蛋白>250 μg/g及转换后英夫利西单抗血清水平未升高与复发风险升高相关。

核心结论

  • 从静脉转换为皮下英夫利西单抗120 mg每2周一次是安全的且接受度良好,在炎症性肠病患者中导致较低的复发风险,但接受10 mg/kg每4周方案的患者除外,这些患者需要240 mg每2周一次。

研究设计与样本

  • 多中心观察性研究,纳入184例符合条件且处于临床缓解(部分Mayo评分≤2或Harvey-Bradshaw指数≤4)的炎症性肠病患者。
  • 其中72.3%(184例中133例)同意转换为皮下英夫利西单抗120 mg每2周一次。
  • 在基线、第1次访视(转换后4-8周)、第2次访视(转换后8-16周)和第3次访视(转换后16-24周)收集药理学和生物学数据。

主要发现

  • 第3次访视时,接受5 mg/kg每8周、10 mg/kg每8周、10 mg/kg每6周和10 mg/kg每4周的患者复发率分别为10.2%(59例中6例)、7.3%(38例中3例)、16.7%(18例中3例)和66.7%(15例中10例)(P < .001)。
  • 剂量递增至240 mg每2周一次使93.3%(15例中14例)的患者重新获得临床缓解。
  • 转换后英夫利西单抗血清水平升高(P < .0001),但接受10 mg/kg每4周方案的患者除外。
  • 多变量分析中,10 mg/kg每4周方案(比值比12.4;95%置信区间1.6-98.4;P = .017)和基线粪钙卫蛋白>250 μg/g(比值比5.4;95%置信区间1.1-27.6;P = .042)与更高的复发风险相关;与基线至第1次访视期间英夫利西单抗血清水平升高(12.7%)相比,血清水平降低(41.7%)或稳定(36.8%)也与更高的复发风险相关(P = .020和P = .019)。
  • 患者接受度(10分制)在转换后改善(6.9 ± 1.6 vs 8.6 ± 1.4;P < .0001),未报告严重不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: We assessed the effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases (IBDs) treated with or without intensified intravenous regimen. METHODS: In this multicenter observational study, IBD patients in clinical remission (partial Mayo score ≤2 or Harvey-Bradshaw index ≤4) were switched to a unique dose of subcutaneous infliximab (120 mg every other week). Pharmacological and biological data were collected at baseline, visit 1 (4-8 weeks postswitch), visit 2 (8-16 weeks postswitch), and visit 3 (16-24 weeks postswitch). Relapse was defined as clinical relapse or fecal calprotectin increase ≥150 μg/g compared with baseline. RESULTS: Among 184 eligible patients, 72.3% (n = 133 of 184) agreed to switch to subcutaneous infliximab. At visit 3, a relapse occurred in 10.2% (n = 6 of 59), 7.3% (n = 3 of 38), 16.7% (n = 3 of 18), and 66.7% (n = 10 of 15) (P < .001) of patients receiving 5 mg/kg every 8 weeks, 10 mg/kg every 8 weeks, 10 mg/kg every 6 weeks, and 10 mg/kg every 4 weeks, respectively. Dose escalation to 240 mg every other week led to recapture clinical remission in 93.3% (n = 14 of 15). Infliximab serum levels increased after the switch (P < .0001) except for patients receiving 10 mg/kg every 4 weeks. In multivariable analysis, 10 mg/kg every 4 weeks regimen (odds ratio, 12.4; 95% confidence interval, 1.6-98.4; P = .017) and fecal calprotectin >250 μg/g at baseline (odds ratio, 5.4; 95% confidence interval, 1.1-27.6; P = .042) had a higher risk of relapse as well as reduced (41.7%) or stable (36.8%) infliximab serum levels between baseline and visit 1 compared with increased serum levels (12.7%) (P = .020 and P = .019, respectively). Patients' acceptability (10-point scale) was improved by the switch (6.9 ± 1.6 vs 8.6 ± 1.4; P < .0001). No severe adverse event was reported. CONCLUSIONS: Switching from intravenous to subcutaneous infliximab 120 mg every other week is safe and well accepted, leading to a low risk of relapse in IBD patients except for those receiving 10 mg/kg every 4 weeks requiring 240 mg every other week.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Buisson A, Nachury M, Reymond M, et al. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clin Gastroenterol Hepatol. 2022. PMID: 35987302. doi:10.1016/j.cgh.2022.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。